Thirona Bio

Thirona Bio Focuses on Developing Drugs for Fibrotic Diseases. Target Indications Include Scleroderma, Keloids, and Certain Cancers Without Effective Therapies. The Company's Unique Approach Uses an Effective Topical Drug to "Locally" Inhibit TGF-β, Minimizing the Potential Risk of Systemic Toxicity. Headquartered in San Diego, California, Thirona is Developing a Novel Compound, FBM5712, Designed to Prevent or Reduce Fibrosis. FBM5712 is a Novel Small Molecule Inhibitor of ALK-5 Kinase (TGF-β Receptor Kinase).